2014 Press Releases

Receive E-mail AlertsEmail Alerts
Sign up to receive e-mail alerts whenever MannKind has a news release. Just enter your e-mail address and click submit.
2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
04/07/14MannKind Updates Status of New Drug Application for AFREZZA(R)
VALENCIA, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA® by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA's requests. About AFREZZA® AFREZZA® (uh-FREZZ-uh) is a novel, ultra rapid-acting mealtime insulin therapy developed by MannKind Co... 
Printer Friendly Version
04/01/14FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes
VALENCIA, Calif., April 1, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 13 to 1 to recommend that AFREZZA® (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted marketing approval by the FDA to improve gl... 
Printer Friendly Version
02/19/14MannKind Corporation to Present at Upcoming Conferences
VALENCIA, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences. The RBC Capital Markets 2014 Global Healthcare Conference on February 25, 2014 at 11:30 AM (ET) at The New York Palace in New York, New York.   Cowen and Company 34th Annual Health Care Conference on March 3, 2014 at 3:30 PM (ET) at the Boston Marriott Copley i... 
Printer Friendly Version
02/18/14MannKind Corporation Reports 2013 Fourth Quarter and Full Year Financial Results
Conference Call to Begin Today at 5:00 PM ET VALENCIA, Calif., Feb. 18, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2013. For the fourth quarter of 2013, total operating expenses were $46.6 million, compared to $33.5 million for the fourth quarter of 2012, an increase of $13.1 million. Research and development (R&D) expenses were $29.0 million for the fourth quarter of 2013, compared... 
Printer Friendly Version
02/04/14MannKind Corporation to Hold 2013 Fourth Quarter and Full Year Financial Results Conference Call on February 18, 2014
VALENCIA, Calif., Feb. 4, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2013 fourth quarter and full year financial results on Tuesday, February 18, 2014 and its management will host a conference call to discuss the fourth quarter and full year financial results and other Company developments at 5:00 PM (Eastern Time) on February 18, 2014. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief Operating Of... 
Printer Friendly Version
01/10/14MannKind Announces Tentative Date of FDA Advisory Committee Review of AFREZZA
Endocrinologic and Metabolic Drugs Advisory Committee Meeting Tentatively Scheduled for April 1, 2014 VALENCIA, Calif., Jan. 10, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is tentatively scheduled on April 1, 2014 to review MannKind's New Drug Application (NDA) for AFREZZA® (insulin human [rDNA origin]) Inhalation Powder. The date and details of the meet... 
Printer Friendly Version
01/08/14MannKind Corporation to Present at the J.P. Morgan 2014 Healthcare Conference
VALENCIA, Calif., Jan. 8, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the J.P. Morgan 2014 Healthcare Conference on Wednesday, January 15, 2014 at 7:30 AM (PST) at Westin St. Francis Hotel in San Francisco, California. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at... 
Printer Friendly Version


Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet